Heritage Family Offices LLP lifted its holdings in shares of Balchem Co. (NASDAQ:BCPC – Free Report) by 8.3% in the 4th quarter, HoldingsChannel reports. The fund owned 1,420 shares of the basic materials company’s stock after purchasing an additional 109 shares during the period. Heritage Family Offices LLP’s holdings in Balchem were worth $231,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Westside Investment Management Inc. bought a new stake in Balchem during the 3rd quarter worth approximately $27,000. nVerses Capital LLC bought a new stake in Balchem during the third quarter worth $35,000. Wilmington Savings Fund Society FSB purchased a new stake in Balchem in the 3rd quarter valued at $35,000. GAMMA Investing LLC lifted its stake in Balchem by 73.4% during the 3rd quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company’s stock valued at $148,000 after acquiring an additional 356 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Balchem by 642.5% during the 3rd quarter. Blue Trust Inc. now owns 839 shares of the basic materials company’s stock worth $148,000 after acquiring an additional 726 shares during the last quarter. Institutional investors and hedge funds own 87.91% of the company’s stock.
Balchem Trading Up 0.2 %
NASDAQ BCPC opened at $160.51 on Friday. The business’s fifty day moving average is $170.98 and its 200-day moving average is $170.73. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90. The stock has a market capitalization of $5.22 billion, a price-to-earnings ratio of 43.15, a PEG ratio of 4.15 and a beta of 0.69. Balchem Co. has a one year low of $135.84 and a one year high of $186.03.
Balchem Increases Dividend
Wall Street Analyst Weigh In
BCPC has been the topic of a number of recent analyst reports. StockNews.com raised shares of Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th. HC Wainwright boosted their target price on Balchem from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.
View Our Latest Stock Analysis on BCPC
Balchem Profile
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Recommended Stories
- Five stocks we like better than Balchem
- Airline Stocks – Top Airline Stocks to Buy Now
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- Short Selling – The Pros and Cons
- Micron Technology: Riding the AI Wave to Long-Term Growth
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC – Free Report).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.